Is new always better than old? The development of human vaccines for anthrax

被引:35
作者
Baillie, Leslie W. [1 ]
机构
[1] Cardiff Univ, Welsh Sch Pharm, Cardiff, Wales
来源
HUMAN VACCINES | 2009年 / 5卷 / 12期
基金
美国国家卫生研究院;
关键词
anthrax; vaccine; Bacillus anthracis; immunity; pathogenicity; RECOMBINANT PROTECTIVE ANTIGEN; ADENOVIRUS-BASED VACCINE; BACILLUS-ANTHRACIS; LETHAL TOXIN; IMMUNE-RESPONSE; NASAL IMMUNIZATION; ANTIBODY-RESPONSES; POSTEXPOSURE PROPHYLAXIS; CPG OLIGONUCLEOTIDES; SUBOPTIMAL AMOUNTS;
D O I
10.4161/hv.9777
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Anthrax is caused by a Gram-positive aerobic spore-forming bacillus called Bacillus anthracis. Although primarily a disease of animals, it can also infect man, sometimes with fatal consequences. As a result of concerns over the illicit use of this organism, considerable effort is focused on the development of therapies capable of conferring protection against anthrax. While effective concerns over the toxicity of the current vaccines have driven the development of second-generation products. Recombinant Protective Antigen (rPA), the nontoxic cell-binding component of anthrax lethal toxin, is the principal immunogen of the vaccines currently undergoing human clinical trials. While these new vaccines are likely to show reduced side effects they will still require multiple needle based dosing and the inclusion of the adjuvant alum which will make them expensive to administer and stockpile. To address these issues, researchers are seeking to develop vaccine formulations capable of stimulating rapid protection following needle-free injection which are stable at room temperature to facilitate stockpiling and mass vaccination programs. Recent concerns over the potential use of molecular biology to engineer vaccine resistant strains has prompted investigators to identify additional vaccine targets with which to extend the spectrum of protection conferred by rPA. While the injection of research dollars has seen a dramatic expansion of the anthrax vaccine field it is sobering to remember that work to develop the current second generation vaccines began around the time of the first gulf war. Almost two decades and millions of dollars later we still do not have a replacement vaccine and even when we do some argue that the spectrum of protection that it confers will not be as broad as the vaccine it replaces. If we are to respond effectively to emerging biological threats we need to develop processes that generate protective vaccines in a meaningful time frame and yield products in months not decades!
引用
收藏
页码:806 / 816
页数:11
相关论文
共 133 条
[1]   Sequence analysis of the genes encoding for the major virulence factors of Bacillus anthracis vaccine strain 'Carbosap' [J].
Adone, R ;
Pasquali, P ;
La Rosa, G ;
Marianelli, C ;
Muscillo, M ;
Fasanella, A ;
Francia, M ;
Ciuchini, F .
JOURNAL OF APPLIED MICROBIOLOGY, 2002, 93 (01) :117-121
[2]   Oral spore vaccine based on live attenuated nontoxinogenic Bacillus anthracis expressing recombinant mutant protective antigen [J].
Aloni-Grinstein, R ;
Gat, O ;
Altboum, Z ;
Velan, B ;
Cohen, S ;
Shafferman, A .
INFECTION AND IMMUNITY, 2005, 73 (07) :4043-4053
[3]  
ANDERS M, 1999, VACCINE, V17, P2067
[4]   Bioterrorism: From threat to reality [J].
Atlas, RM .
ANNUAL REVIEW OF MICROBIOLOGY, 2002, 56 :167-185
[5]   Role of superoxide in the germination of Bacillus anthracis endospores [J].
Baillie, L ;
Hibbs, S ;
Tsai, P ;
Cao, GL ;
Rosen, GM .
FEMS MICROBIOLOGY LETTERS, 2005, 245 (01) :33-38
[6]   Characterization of the human immune response to the UK anthrax vaccine [J].
Baillie, L ;
Townend, T ;
Walker, N ;
Eriksson, U ;
Williamson, D .
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 2004, 42 (02) :267-270
[7]   The development of new vaccines against Bacillus anthracis [J].
Baillie, L .
JOURNAL OF APPLIED MICROBIOLOGY, 2001, 91 (04) :609-613
[8]   Bacillus anthracis, a bug with attitude! [J].
Baillie, L ;
Read, TD .
CURRENT OPINION IN MICROBIOLOGY, 2001, 4 (01) :78-81
[9]  
BAILLIE L, ANTHRAX VACCIN UNPUB
[10]   Past, imminent and future human medical countermeasures for anthrax [J].
Baillie, L. W. J. .
JOURNAL OF APPLIED MICROBIOLOGY, 2006, 101 (03) :594-606